-
Mashup Score: 0
Objective Most men undergoing androgen deprivation therapy (ADT) for prostate cancer experience hot flushes. Current treatments have low or limited evidence of efficacy. It is likely that oestradiol depletion is the mediator of these hot flushes, and transdermal oestradiol might be an effective treatment. Design This is a 6-month randomised, placebo-controlled trial with the hypothesis that…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 011-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing’s disease - 2 year(s) ago
Background Symptoms of hyperandrogenism are common in patients with Cushing’s disease (CD), yet they are not sufficiently explained by androgen concentrations. In this study, we analyzed the contribution of 11-oxygenated C19 steroids (11oxC19) to hyperandrogenemia in female patients with CD. Methods We assessed saliva day profiles in females with CD pre (n = 23) and post (n = 13) successful…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
New research by Hanna F Nowotny et al. analyzes the contribution of 11-Oxygenated C19 steroids #11oxC19 showing that they are the predominant androgens responsible for hyperandrogenemia in Cushing's disease. #OpenAccess #OAWeek @ESEndocrinology https://t.co/P3qL8HCZdr https://t.co/WQ5OCpoaBO
-
-
Mashup Score: 1Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients - 2 year(s) ago
Objective To describe clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT)/pituitary carcinomas (PC). Design Electronic survey August 2020–May 2021. Results 96% of 171 (121 APT, 50 PC), initially presented as macro/giant tumours, 6 were microadenomas (5 corticotroph). Ninety-seven tumours, initially considered clinically benign,…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
A fascinating new paper in EJE by Pia Burman et al. describes the clinical and pathological characteristics and treatment outcomes in a large cohort of aggressive pituitary tumours (APT) / pituitary carcinomas (PC). #OpenAccess #OAWeek @ESEndocrinology https://t.co/trSh5PIcmg https://t.co/JznAkRLGUo
-
-
Mashup Score: 0Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline - 2 year(s) ago
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated with significant autoimmune endocrinopathies that pose both diagnostic and treatment challenges. The aim of this guideline is to provide clinicians with the best possible evidence-based recommendations for treatment and follow-up of patients with ICI-induced endocrine side-effects based on the Grading of…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
***NEW CLINICAL PRACTICE GUIDELINE*** 'Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice' by Eystein S Husebye et al. @ESEndocrinology https://t.co/NnuUn5T8iM https://t.co/ZfXgjEv8ep
-
-
Mashup Score: 0Mosaic PRKACA duplication causing a novel and distinct phenotype of early-onset Cushing syndrome and acral cutaneous mucinosis - 2 year(s) ago
Genetic alterations within the cAMP/PKA pathway result in a spectrum of adrenocortical disorders. Implicated genes include GNAS, PDE8, PDE11A, PRKAR1A/B, and PRKACA. To date, somatic PRKACA mutations and germline PRKACA copy number gain have been associated with the development of cortisol-secreting adrenocortical adenomas and bilateral adrenal hyperplasia, respectively. While perturbations…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
"It suggests that the Cushing syndrome phenotypes arising from somatic and germline PRKACA abnormalities likely exist on a spectrum." Mosaic PRKACA duplication causing early-onset Cushing syndrome and acral cutaneous mucinosis https://t.co/GNSE0OD158
-
-
Mashup Score: 5Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus - 2 year(s) ago
‘What’s in a name? That which we call a rose/By any other name would smell as sweet.’ (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence,…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
Protecting patients' lives is a matter of the utmost importance. Changing the name of diabetes insipidus will ensure future patients receive appropriate care for their condition https://t.co/gWaZbITviM @ESEndocrinology https://t.co/IFpfPrImqi
-
-
Mashup Score: 1Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus - 2 year(s) ago
‘What’s in a name? That which we call a rose/By any other name would smell as sweet.’ (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare’s implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence,…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
Diabetes mellitus vs diabetes insipidus: two very different conditions that often get mixed up, leading to the wrong treatment being given to patients. There is a call for a name change of the latter to stop further confusion: https://t.co/Fec1B0N63Y @ESEndocrinology https://t.co/6sQj6p0m9M
-
-
Mashup Score: 0Cardiovascular risk in Danish transgender persons: a matched historical cohort study - 2 year(s) ago
Background Cardiovascular risk could be increased in transgender persons, but the mechanism is undetermined. Aim The aim of this study was to assess the risk of cardiovascular outcomes in Danish transgender persons compared to controls. Methods The study design was a historical register-based cohort study in Danish transgenders and age-matched controls. The main outcome measure was cardiovascular…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
@SimbaComics @EYEScientists @ESEndocrinology @EsePresident Read the full article by Dorte Glintborg et al. (2022), Cardiovascular risk in Danish transgender persons: a matched historical cohort study. European Journal of Endocrinology, 187(3), 463-477. https://t.co/ddSUxiuGnS #CoMICsWednesdays #EJECoMICs
-
-
Mashup Score: 1MECHANISMS IN ENDOCRINOLOGY: The pathophysiology of transient congenital hypothyroidism - 2 year(s) ago
Transient congenital hypothyroidism (TCH) refers to congenital hypothyroidism which spontaneously resolves in the first few months or years of life. Currently, there is a paucity of reliable markers predicting TCH at diagnosis, and the diagnosis is established following the withdrawal of levothyroxine therapy around 3 years of age. The incidence of TCH is increasing, and it is a major contributor…
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
Catherine Peters and Nadia Schoenmakers have written a review: MECHANISMS IN ENDOCRINOLOGY: The pathophysiology of transient congenital hypothyroidism. https://t.co/u42wXMPj7V https://t.co/JZKMvGFTVr
-
-
Mashup Score: 0
During the last decades, knowledge of the molecular biology in medullary thyroid carcinoma (MTC) and specifically on the role of rearranged during transfection (RET)-activating mutations in tumorigenesis has led to the evolution of novel targeted therapies, mainly tyrosine kinase inhibitors (TKIs). Vandetanib and cabozantinib have been approved for the management of metastatic progressive MTC….
Source: ejeCategories: Endocrinology, Latest HeadlinesTweet-
New review published: 'MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives' by Katerina Saltiki et al. https://t.co/cXvQxh15hO https://t.co/mCmoMnvtLO
-
Read the full article by Nicholas Russell et al. (2022), Effects of oestradiol treatment on hot flushes in men undergoing androgen deprivation therapy for prostate cancer. European Journal of Endocrinology, 187(5), 617-627. https://t.co/zFjQAPETwN #CoMICWednesday #EJECoMICs https://t.co/jbEbBwodtb